Prussian Blue Drug Products — Submitting a New Drug Application

Description

This guidance is intended to assist manufacturers wishing to submit new drug applications (NDAs) for prussian blue drug products for the treatment of internal contamination with radioactive thallium, nonradioactive thallium, or radioactive cesium. The Federal Register notice announcing the availability of this guidances explains in detail the Agency's findings regarding safety and effectiveness and includes a list of the literature on which it based those findings.

Scope & Applicability

Regulatory Context

• 21CFR314.101§ 314.101 Filing an NDA and receiving an ANDA.

  (a) Filing an NDA.Read full regulation →

• 21CFR314.50§ 314.50 Content and format of an NDA.

  NDAs and supplements to approved NDAs are required to be submitted in the form and contain the information, as appropriate for the particular submission, required under this section. Three copies of the NDA are required: An archival copy, a review copy, and a field copy. An NDA for a new chemical enRead full regulation →

• Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA) (Status: Final)
• Calcium DTPA and Zinc DTPA Drug Products-Submitting a New Drug Application (Status: Final)
• Interpreting Sameness of Monoclonal Antibody Products Under the Orphan Drug Regulations (Status: Final)
• Meetings with the Office of Orphan Products Development: Guidance for Industry, Researchers, Patient Groups, and Food and Drug Administration Staff (Status: Final)
• Tropical Disease Priority Review Vouchers (Status: Final)
• Rare Pediatric Disease Priority Review Vouchers: Draft Guidance for Industry (Status: Draft)
• Questions and Answers on Biosimilar Development and the BPCI Act Guidance for Industry: Guidance for Industry (Status: Final)
• Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations: Guidance for Industry (Status: Final)